Hangzhou Tigermed Consulting Co., Ltd. Class A

Hangzhou Tigermed Consulting Co., Ltd. Class A

4.10
EUR
-0.02
(-0.49%)
-0.06EPS
7.04BMarket Cap
Mar 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.34
0.63
0.96
1.09
1.5
2.01
2.46
2.63
3.93
5.36
5.58
5.01
5.24
8.05
Basic EPS, GAAP
0.1
0.13
0.16
0.13
0.27
0.41
0.74
1.44
2.17
1.52
1.53
0.31
0.68
-0.43
Free Cash Flow per Basic Share
0.04
0.01
0.1
0.12
0.24
0.38
0.37
0.69
0.8
0.69
0.63
0.56
0.69
- -
Dividend per Share
0.04
0.05
0.05
0.06
0.06
0.11
0.23
0.22
0.21
0.37
0.45
0.49
0.26
0.21
Book Value per Share
0.76
0.88
1.01
1.49
2.17
2.48
3.69
12.09
13.59
14.69
15.77
15.64
15.93
14.93
Tangible Book Value per Share
0.73
0.51
0.52
0.93
1.24
1.55
2.59
10.9
12.07
12.57
13.42
12.94
13.04
12.13
Basic Weighted Avg Shares
980
992
995
1,075
1,127
1,145
1,138
1,215
1,327
1,322
1,322
1,317
1,305
944
Sales/Revenue/Turnover
337
625
957
1,175
1,687
2,301
2,803
3,192
5,214
7,085
7,384
6,603
6,833
7,598
Operating Margin (%)
27.32
26.32
22.95
15.22
23.85
23.05
26.79
27.55
26.43
25.56
23.78
16.17
9.76
10.11
Depreciation Expense
4
12
31
35
31
58
43
145
189
265
306
324
327
- -
Net Income, GAAP
94
125
156
141
301
472
842
1,750
2,874
2,007
2,025
405
888
-405
Effective Tax Rate (%)
14.49
20.54
21.03
26.07
22.97
16.38
10.45
8.55
7.95
12.13
13.61
32.6
19.75
- -
Profit Margin (%)
27.95
20.09
16.33
11.98
17.84
20.52
30.02
54.81
55.13
28.32
27.42
6.14
12.99
-5.32
Working Capital
629
400
217
659
612
385
1,560
10,507
8,439
7,378
7,205
2,638
3,342
4,148
LT Debt
- -
12
7
16
17
110
172
279
407
734
857
723
964
1,831
Total Equity
755
917
1,066
1,840
2,801
3,272
5,521
17,858
20,605
22,681
24,454
24,064
24,256
23,261
Return on Invested Capital (%)
12
13.66
13.19
8.7
12.43
13.88
18.18
16.28
16.87
9.53
8.02
1.63
3.06
- -
Return on Capital (%)
11.45
12.05
11.14
7.77
10.78
12.67
13.99
12.21
11.89
7.68
7.51
1.67
3.95
- -
Return on Common Equity (%)
13.12
15.61
16.75
10.7
14.62
17.72
23.83
17.2
16.79
10.64
9.97
1.94
4.27
-2.01

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
596
410
387
LT Borrowings
780
1,627
1,526
LT Finance Leases
345
307
305
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,316
1,316
1,316
Market Capitalization
47,835
40,181
53,484

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
6,629
6,608
6,837
Cash, Cash Equivalents & STI
2,201
2,127
2,118
Accounts Receivable, Net
1,360
1,332
1,424
Inventories
56
66
63
Total Current Liabilities
2,880
2,659
2,688
Payables & Accruals
- -
- -
- -
ST Debt
596
410
387
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
46.63%
6.5%
0.8%
Free Cash Flow
30.96%
2.81%
22.05%
Net Income, GAAP
42.11%
14.83%
119.15%
Sales/Revenue/Turnover
23.48%
19.27%
3.48%
Total Cash Common Dividend
30.43%
12.03%
-46.48%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,660
1,698
1,709
1,536
6,603
2025
1,564
1,686
- -
1,807
6,833
2026
1,801
1,906
2,084
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.18
0.3
0.37
-0.47
0.31
2025
0.12
0.26
- -
-0.15
0.68
2026
0.04
-0.55
0.17
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.04
0.63
0.04
0.49
2025
0.02
0.29
- -
- -
0.26
2026
0.01
0.03
0.18
- -
- -

Company Description

CEO
Zeng Yu Wen
Full Time Employees
11,130
Sector
Health technology
Industry
Biotechnology
Address
No. 508, Lujiatan Street Hangzhou TJ China 310051
IPO Date
Aug 17, 2012
Business
Hangzhou Tigermed Consulting Co., Ltd. is a leading contract research organization (CRO) specializing in comprehensive clinical research services for the pharmaceutical, biotechnology, and medical device industries. Founded in 2004 and headquartered in Hangzhou, China, the company offers a wide range of core services including technical support for Phase I to Phase IV clinical trials; clinical trial management; data management and biostatistics; regulatory affairs consultancy; pharmacovigilance; site management and monitoring; and medical writing. Tigermed’s service portfolio spans preclinical research such as medicinal chemistry, compound screening, drug metabolism, pharmacokinetics, safety and toxicology, bioanalytical services, and formulation research and development. The company operates globally with significant presence across Asia, the United States, Europe, and other regions through subsidiaries and strategic partnerships. In recent developments, Tigermed has made strategic investments and expansions to reinforce its market-leading position. In the first half of 2024, Tigermed acquired the China division of NAMSA, a renowned medical device CRO, and entered into an exclusive strategic cooperation agreement with NAMSA for China and global collaboration. The company notably expanded its pharmacovigilance team by establishing a local unit in the U.S., signed more than 80 new projects, and gained over 100 new clients, reflecting rapid growth in this regulatory compliance segment. Tigermed also facilitated the approval of multiple new drugs and innovative medical devices in China, the U.S., and Japan, supporting over 2,000 ongoing site management projects and nearly 1,000 data management and statistical analysis projects as of mid-2024. Additionally, the launch of a Solutions Business Unit aims to provide integrated, one-stop services for multinational corporations (MNCs) on China projects, while Tigermed accelerates its investments and brand-building efforts in key overseas markets such as the U.S., Australia, and Europe. The company’s significant collaborations and partnership-driven approach underpin its geographical and service expansion, covering more than 30 countries. Tigermed leverages advanced technology platforms, including AI-driven data analytics, to enhance clinical trial efficiency and quality. It supports extensive therapeutic areas including oncology, cardiovascular, infectious diseases, respiratory, hematology, orthopedics, and vaccines. Tigermed’s client base includes global pharmaceutical, biotech, and medical device companies seeking reliable, regulatory-compliant clinical development support. The firm emphasizes operational excellence, innovation, and ethical compliance, which has led to a strong market share in China’s clinical CRO sector and steady growth internationally. Hangzhou Tigermed Consulting Co., Ltd. remains focused on advancing drug and device development through integrated R&D service platforms, facilitating faster regulatory approval processes, and expanding its service breadth from clinical trial management to post-marketing pharmacovigilance and regulatory consulting. Its forward-looking strategy emphasizes expanding global presence, enhancing technology adoption, and sustaining collaborative ties with multinational industry leaders to improve patient outcomes worldwide. This approach has driven Tigermed’s robust financial performance, with notable revenue growth, increased profitability, and ongoing investments in R&D to sustain leadership in the fast-evolving clinical research industry.